<DOC>
	<DOCNO>NCT00033735</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . It yet know whether irofulven effective treat pancreatic cancer . PURPOSE : Randomized phase III trial compare effectiveness irofulven fluorouracil treat patient locally advance metastatic pancreatic cancer respond previous treatment gemcitabine .</brief_summary>
	<brief_title>Irofulven Compared With Fluorouracil Treating Patients With Pancreatic Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Compare survival patient gemcitabine-refractory , advanced pancreatic adenocarcinoma treat irofulven v fluorouracil . II . Compare objective tumor response rate patient treat regimen . III . Compare clinical benefit regimen measure improvement pain performance status patient . OUTLINE : This randomize , open-label , multicenter study . Patients randomize 2:1 irofulven fluorouracil treatment arm . Arm I : Patients receive irofulven IV 30 minute day 1 15 . Arm II : Patients receive fluorouracil IV continuously day 1-28 . Courses repeat every 28 day . PROJECTED ACCRUAL : Approximately 350 patient ( 233 arm I 117 arm II ) accrue study .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Irofulven</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm ductal carcinoma exocrine pancreas Locally advance metastatic Failed 1 , 1 , prior gemcitabinecontaining chemotherapy regimen ( either single agent combination another agent ) ( See criterion prior radiation use gemcitabine fluorouracil diminish dos Prior/Concurrent Therapy section ) No neuroendocrine islet cell tumor lymphoma pancreas PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 70100 % Life expectancy : Not specify Hematopoietic : WBC least 3,000/mm3 Platelet count least 100,000/mm3 Hemoglobin least 9 g/dL Absolute neutrophil count least 1,500/mm3 Hepatic : Bilirubin great 2.0 mg/dL AST ALT great 5.0 time upper limit normal ( ULN ) Alkaline phosphatase great 5.0 time ULN Renal : Creatinine great 1.5 mg/dL Cardiovascular : No clinically significant active heart disease Other : Fertile patient must use effective contraception No history retinopathy macular degeneration No malignancy within past 5 year except basal cell squamous cell skin cancer carcinoma situ cervix No significant medical and/or psychiatric condition would preclude study PRIOR CONCURRENT THERAPY : Biologic therapy : No prior biologic therapy No concurrent biologic therapy Chemotherapy : See Disease Characteristics At least 21 day since prior chemotherapy recover No prior systemic treatment fluorouracil , fluorouraciluracil , raltitrexed , capecitabine combination gemcitabine Prior fluorouracil gemcitabine allow radiosensitizing agent give 2 week , , 2 week radiotherapy No prior cumulative mitomycin dose great 25 mg/m2 Endocrine therapy : Not specify Radiotherapy : At least 21 day since prior radiotherapy recover Surgery : No prior surgery No concurrent surgery Other : At least 21 day since prior participation investigational study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>recurrent pancreatic cancer</keyword>
	<keyword>duct cell adenocarcinoma pancreas</keyword>
</DOC>